MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6970-6979

  Cruciani, Gabriele ^a   Carosati, Emanuele ^a   De Boeck, Benoit ^b   Ethirajulu, Kantharaj ^b   Mackie, Claire ^b   Howe, Trevor ^b   Vianello, Riccardo ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Molecular Discovery Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME; CYTOCHROME P450; PRODRUG;

ARTICLE; AUTOMATION; BIOTRANSFORMATION; CHEMISTRY; COMPUTER MODEL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; METHODOLOGY;

AMPHETAMINES; AZETIDINES; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; DRUG DESIGN; EUGENOL; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHTHALIMIDES; PROPANOLAMINES; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 27444434892     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050529c     Document Type: Article

References (53)

1. 2A receptor antagonists. J. Med. Chem. 2001, 44, 1603-1614.
2. Korzekwa, K. R.; Grogan, J.; DeVito, S.; Jones, J. P. Electronic models for cytochrome P450 oxidations. Adv. Exp. Med. Biol. 1996, 38, 361-369.
3. Lewis, D. F.; Dickins, M.; Eddershaw, P. J.; Tarbit, M. H.; Goldfarb, P. S. Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries. Drug Metab. Drug Interact. 1999, 15, 1-49.
4. De Groot, M. J.; Ackland, M.; Home, V.; Alexander, A.; Barry, J. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 1999, 42, 4062-4070.
5. Jones, B. C.; Hawksworth, G.; Home, V. A.; Newlands, A.; Morsman, J.; Tute, M. S.; Smith, D. A. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab. Dispos. 1996, 24, 260-266.
6. Mancy, A.; Broto, P.; Dijols, S.; Dansette, P. M.; Mansuy, D. The Substrate binding site of human liver cytochrome P450 2C9: An approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 1995, 34, 10365-10375.
7. Riddestrom, M.; Zamora, I.; Fjäström, O.; Andersson, T. B. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J. Med. Chem. 2001, 44, 4072-4081.
8. Singh, S. B.; Shen, L. Q.; Walker, M. J.; Sheridan, R. A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. J. Med. Chem. 2003, 46, 1330-1336.
9. Chen, H.; de Groot, M.; Vermulen, N.; Hanzlik, R. P. Oxidative N-dealkylation of p-cyclopropyl-N,N-dimethylaniline. A substituent effect on a radical-clock reaction rationalized by ab initio calculations on radical cation intermediates. J. Org. Chem. 1997, 62, 8227-8230.
10. Visser, S. P.; Ogliaro, F.; Sharma, P. K.; Shaik, S. What factors affect the regioselectivity of oxidation by cytochrome P450? A DFT study of allylic hydroxylation and double bond epoxidation in a model reaction. J. Am. Chem. Soc. 2002, 124, 11809-11826.
11. Darvas, F.; Marokhazi, S.; Kormos, P.; Kulkarmi, G.; Kalasz, H.; Papp, A. MetabolExpert: Its Use in Metabolism Research and in Combinatorial Chemistry. In Drug Metabolism; Erhardt, P. W., Ed.; Blackwell Science: Oxford, 1999; pp 237-270.
12. Zamora, I.; Afzelius, L.; Cruciani, G. Predicting drug metabolism: A site of metabolism prediction tool applied to the cytochrome P450 2C9. J. Med. Chem. 2003, 46, 2313-2324.
13. 2 angiotensin II receptor antagonists. J. Med. Chem. 2005, 48, 4389-4399.
14. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. http://www.pdb.org, 2004, 1R90 entry.
15. Yano, J. K.; Wester, M. R.; Schoch, G. A., Griffin, K. J.; Stout, C. D.; Johnson, E. F. http://www.pdb.org, 2004, 1TQN entry.
16. Open-shell radicals were optimized at the AM1 semiempirical level. Single-point energy evaluations were performed by DFT at the B3LYP/6-311G** level of theory because correlation between experimental and calculated radical stabilities resulted in reasonable agreement for this level of theory.
17. Kudo, S.; Uchida, M.; Odomi, M. Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur. J. Clin. Pharmacol. 1997, 52, 479-485.
18. Pritchard, J. F. Ondansetron metabolism and pharmacokinetics. Semin. Oncol. 1992, 19, 9-15.
19. de Graaf, C.; Vermeulen, N. P. E.; Feenstra, K. A. Cytochrome P450 in silico: An integrative modeling approach. J. Med. Chem. 2005, 48, 2725-2755.
20. Katsuhisa, S.; Yuji, I.; Shinji, O.; Yusuke, H.; Shosuke, K. Copper-mediated oxidative DNA damage induced by eugenol: possible involvement of O-demethylation. Mutat. Res. 2004, 565, 35-44.
21. Thomas, S. R.; Gerhard, U. Open-access high-resolution mass spectrometry in early drug discovery. J. Mass Spectrom. 2004, 39, 942-948.
22. Kantharaj, E.; Tuytelaars, A.; Proost, P.; Ongel, Z.; Assouw, H. P.; Gilissen, R. A. Simultaneous measurement of drug metabolic stability and identification of metabolities using ion-trap mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17, 2661-2668.
23. Kostiainen, R.; Kotiano, T.; Kuuranne, T.; Auriola, S. Liquid chromatography-atmospheric pressure ionization/mass spectrometry (LC-API/MS) in Drug Metabolism Studies. J. Mass Spectrom. 2003, 38, 357-372.
24. Corcoran, O.; Spraul, M. LC-NMR-MS in drug discovery. Drug Discovery Today 2003, 8, 624-631.
25. Nassar, A. E. F.; Talaat, R. E. Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discovery Today 2004, 9, 317-327.
26. Mooers, C. N. Why some retrieval systems are used and others are not. Bull. Am. Soc. Inf. Sci. 1996, 23, 22-23.
27. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
28. Carosati, E.; Sciabola, S.; Cruciani, G. Hydrogen bonding interactions of covalently bonded fluorine atoms: From crystallographic data to a new angular function in the GRID force field. J. Med. Chem. 2004, 47, 5114-5125.
29. Goodford, P. J. Atom Movements during Drug-Receptor Interactions. In Rational Molecular Design in Drug Research; Liljefors, T., Jorgensen, F. S., Krogsgaard-Larsen, P., Eds.; Alfred Benzon Symposium 42; Munkgaard: Copenhagen, 1998; pp 215-230.
30. MetaSite, version 2.5; Molecular Discovery Ltd., 2004 (http://www.moldiscovery.com).
31. Cai, Z.; Sinhababu, A. K.; Harrelson, S. Simultaneous quantitative cassette analysis of drugs and detection of their metabolites by high performance liquid chromatography/ion trap mass spectrometry. Rapid Commun. Mass Spectrom. 2000, 14, 1637-1643.
32. Kantharaj, E.; Ehmer, P. B.; Tuytelaars, A.; Van Vlaslaer, A.; Mackie, C.; Gilissen, R. A. H. J. Simultaneous measurements of metabolic stability and metabolite identification of 7-meth-oxymethylthiazolo[3,2-a]pyrimidin-5-one derivatives in human liver microsomes using liquid chromatography/ion-trap mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19, 1069-1074.
33. Trinks, U.; Buchdunger, E.; Furet, P.; Kump, W.; Mett, H.; Meyer, T.; Muller, M.; Regenass, U.; Rihs, G.; Lydon, N. Dianilinophthalimides: Potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1994, 37, 1015-1027.
34. Floyd, D. M.; Kimball, S. D.; Krapcho, J.; Das, J.; Turk, C. F.; Moquin, R. V.; Lago, M. W.; Duff, K. J.; Lee, V. G.; White, R. E.; Ridgewell, R. E.; Moreland, S.; Brittain, R. J.; Normandin, D. E.; Hedberg, S. A.; Cucinotta, G. G. Benzazepinone calcium channel blockers. 2. Structure activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones. J. Med. Chem. 1992, 35, 756-772.
35. Smith, D. A.; Waterbeemd, H.; Walker, D. K. In Pharmacokinetic and Metabolism in Drug Design; Mannhold, R., Kubinyi, H., Timmerman, H., Eds.; Wiley-VCH: Weinheim, Germany, 2001; Vol. 13, p 84.
36. Rosemblum, S. B.; Huynh, T.; Afonso, A.; Davis, H. R.; Yumibe, N.; Clader, J. W.; Burnett, D. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4- fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 1998, 41, 973-980.
37. Narimatsu, S.; Masubuchi, Y.; Hosokawa, S.; Ohmori, S.; Kitada, M.; Suzuki, T. Involvement of a cytochrome P4502D subfamily in human liver microsomal bunitrolol 4-hydroxylation. Biol. Pharm. Bull. 1994, 17, 803-807.
38. Bach, M. V.; Coutts, R. T.; Baker, G. B. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 1999, 29, 719-732.
39. For 600 substrates of 2C9, 2C19, and 2D6 the average relative importance of the recognition component and reactivity components was 80% and 20%, respectively. For 350 substrates of 3A4 the average relative importance of the recognition component and reactivity components was 65% and 35%, while for 150 substrates of 1A2, it was 70% and 30%, respectively.
40. Cianchetta, G.; Vaz, R. Drug Design I Group, Sanofi-Aventis, Bridgewater, NJ. Personal communication, 2004.
41. Howard, M. PDM Group, Pfizer, Sandwich, U.K. Personal communication, 2005.
42. Cinato, F.; Cocchiara, G. Nerviano Medical Science, Milano, Italy. Personal communication, 2005.
43. Ethirajulu, K.; De Boeck, B. Departments of ADME and Medicinal Chemistry, Johnson and Johnson PRD, Beerse, Belgium. Personal communication, 2004.
44. Afzelius, L. DMPK & Biochem Group, AstraZeneca, Molndal, Sweden. Personal communication, 2005.
45. Pastor, M.; Cruciani, G.; McLay, I.; Pickett, S.; Clementi, S. GRid-INdependent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors. J. Med. Chem. 2000, 43, 3233-3243.
46. Amat, L.; Carbó-Dorca, R. Fitted electronic density functions from H to Rn for use in quantum similarity measures: cis- Diamminedichloroplatinum(II) complex as an application example. J. Comput. Chem. 1999, 20, 911-920.
47. Afzelius, L.; Zamora, I.; Ridderström, M.; Kalén, A.; Andersson, T. B.; Masimirembwa, C. Competitive CYP2C9 inhibitors: Enzyme Inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol. Pharmacol. 2001, 59, 909-919.
48. Jones, J. P.; He, M.; Trager, W. F.; Rettie, A. E. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab. Dispos. 1996, 24, 1-6.
49. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B.; Wikel, J.; Wrighton, S. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab. Dispos. 2000, 28, 994-1002.
50. Guengerich, F. P. Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Arch. Biochem. Biophys. 2003, 409, 59-71.
51. De Rienzo, F.; Fanelli, F.; Menziani, M. C.; De Benedetti, P. G. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J. Comput.-Aided Mol. Des. 2000, 14, 93-116.
52. Rost, B.; Sander, C. Combining evolutionary information and neural networks to predict protein secondary structure. Proteins 1994, 19, 55-72.
53. Magdalou, J.; Fournel-Gigleux, S.; Testa, B.; Ouzzine, M. Biotransformation Reactions. In The Practice of Medicinal Chemistry, 2nd ed.; Wermuth, C. G., Ed.; Academic Press: Amsterdam, 2003; pp 517-544.